nach oben

Arthritis Research & Therapy

Erschienen in:

01.12.2011 | Review

Sjögren's syndrome: studying the disease in mice

verfasst von: Nicolas Delaleu, Cuong Q Nguyen, Ammon B Peck, Roland Jonsson

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Sjögren's syndrome (SS), a systemic autoimmune disease, is characterized by inflammation of exocrine tissues accompanied by a significant loss of their secretory function. Clinical symptoms develop late and there are no diagnostic tests enabling early diagnosis of SS. Thus, particularly to study these covert stages, researchers turn to studying animal models where mice provide great freedom for genetic manipulation and testing the effect of experimental intervention. The present review summarizes current literature pertaining to both spontaneous and extrinsic-factor induced SS-like diseases in mouse models, discussing advantages and disadvantages related to the use of murine models in SS research.

Nur mit Berechtigung zugänglich

Delaleu N, Jonsson R, Koller MM: Sjögren's syndrome. Eur J Oral Sci. 2005, 113: 101-113. 10.1111/j.1600-0722.2004.00183.x.

Jonsson R, Bowman SJ, Gordon TP: Sjögren's syndrome. Arthritis and Allied Conditions. Edited by: Koopman WJ. 2005, Philadelphia, PA: Lippincott Williams & Wilkins, 1681-1705. 15

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002, 61: 554-558. 10.1136/ard.61.6.554.

Theander E, Manthorpe R, Jacobsson LT: Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum. 2004, 50: 1262-1269. 10.1002/art.20176.

Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT: Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006, 65: 796-803. 10.1136/ard.2005.041186.

Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005, 52: 1534-1544. 10.1002/art.21006.

Båve U, Nordmark G, Lövgren T, Ronnelid J, Cajander S, Eloranta ML, Alm GV, Rönnblom L: Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005, 52: 1185-1195. 10.1002/art.20998.

Ronnblom L, Alm GV, Eloranta ML: The type I interferon system in the development of lupus. Semin Immunol. 2011, 23: 113-121. 10.1016/j.smim.2011.01.009.

Garantziotis S, Hollingsworth JW, Zaas AK, Schwartz DA: The effect of toll-like receptors and toll-like receptor genetics in human disease. Annu Rev Med. 2008, 59: 343-359. 10.1146/annurev.med.59.061206.112455.

10.

Dawson LJ, Fox PC, Smith PM: Sjögrens syndrome - the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford). 2006, 45: 792-798. 10.1093/rheumatology/kel067.

11.

Delaleu N, Jonsson MV, Appel S, Jonsson R: New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am. 2008, 34: 833-845. 10.1016/j.rdc.2008.08.004. vii

12.

Cha S, Peck AB, Humphreys-Beher MG: Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med. 2002, 13: 5-16. 10.1177/154411130201300103.

13.

Jonsson MV, Delaleu N, Jonsson R: Animal models of Sjögren's syndrome. Clin Rev Allergy Immunol. 2007, 32: 215-224. 10.1007/s12016-007-8012-7.

14.

Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol. 2004, 172: 2731-2738.

15.

Brown SD, Wurst W, Kuhn R, Hancock JM: The functional annotation of mammalian genomes: the challenge of phenotyping. Annu Rev Genet. 2009, 43: 305-333. 10.1146/annurev-genet-102108-134143.

16.

Shaw DR: Searching the Mouse Genome Informatics (MGI) resources for information on mouse biology from genotype to phenotype. Curr Protoc Bioinformatics. 2009, Chapter 1: Unit1.7-

17.

Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT: A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity. 2005, 23: 115-126. 10.1016/j.immuni.2005.08.002.

18.

Keyes GG, Vickers RA, Kersey JH: Immunopathology of Sjögren-like disease in NZB/NZW mice. J Oral Pathol. 1977, 6: 288-295. 10.1111/j.1600-0714.1977.tb01651.x.

19.

Jonsson R, Tarkowski A, Bäckman K, Klareskog L: Immunohistochemical characterization of sialadenitis in NZB X NZW F1 mice. Clin Immunol Immunopathol. 1987, 42: 93-101. 10.1016/0090-1229(87)90176-0.

20.

Kessler HS: A laboratory model for Sjögren's syndrome. Am J Pathol. 1968, 52: 671-685.

21.

Kessler HS, Cubberly M, Manski W: Eye changes in autoimmune NZB and NZB × NZW mice. Comparison with Sjögren's syndrome. Arch Ophthalmol. 1971, 85: 211-219.

22.

Deshmukh US, Ohyama Y, Bagavant H, Guo X, Gaskin F, Fu SM: Inflammatory stimuli accelerate Sjögren's syndrome-like disease in (NZB × NZW)F1 mice. Arthritis Rheum. 2008, 58: 1318-1323. 10.1002/art.23368.

23.

Hayashi T, Adachi C, Hasegawa K: Systemic treatment of anti-CD4CD25 T cell monoclonal antibody exacerbates sialoadenitis in submandibular glands during the early life in lupus-prone female NZB × NZWF mice. J Oral Pathol Med. 2009, 38: 234-240.

24.

Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H: Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med. 2009, 38: 42-47.

25.

Hang L, Theofilopoulos AN, Dixon FJ: A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med. 1982, 155: 1690-1701. 10.1084/jem.155.6.1690.

26.

Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992, 356: 314-317. 10.1038/356314a0.

27.

Singer GG, Abbas AK: The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity. 1994, 1: 365-371. 10.1016/1074-7613(94)90067-1.

28.

Skarstein K, Nerland AH, Eidsheim M, Mountz JD, Jonsson R: Lymphoid cell accumulation in salivary glands of autoimmune MRL mice can be due to impaired apoptosis. Scand J Immunol. 1997, 46: 373-378. 10.1046/j.1365-3083.1997.d01-142.x.

29.

Jonsson R, Tarkowski A, Backman K, Holmdahl R, Klareskog L: Sialadenitis in the MRL-l mouse: morphological and immunohistochemical characterization of resident and infiltrating cells. Immunology. 1987, 60: 611-616.

30.

Jonsson R, Holmdahl R: Infiltrating mononuclear cells in salivary glands and kidneys in autoimmune MRL/Mp-lpr/lpr mice express IL-2 receptor and produce interferon-gamma. J Oral Pathol Med. 1990, 19: 330-334. 10.1111/j.1600-0714.1990.tb00855.x.

31.

Skarstein K, Johannessen AC, Holmdahl R, Jonsson R: Effects of sialadenitis after cellular transfer in autoimmune MRL/lpr mice. Clin Immunol Immunopathol. 1997, 84: 177-184. 10.1006/clin.1997.4387.

32.

Jonsson R, Pitts A, Mestecky J, Koopman W: Local IgA and IgM rheumatoid factor production in autoimmune MRL/lpr mice. Autoimmunity. 1991, 10: 7-14. 10.3109/08916939108997142.

33.

Haneji N, Hamano H, Yanagi K, Hayashi Y: A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice. J Immunol. 1994, 153: 2769-2777.

34.

Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, Noji S, Sugino H, Hayashi Y: Identification of α-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science. 1997, 276: 604-607. 10.1126/science.276.5312.604.

35.

Zandbelt MM, Vogelzangs J, Van De Putte LB, Van Venrooij WJ, Van Den Hoogen FH: Anti-α-fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome. Arthritis Res Ther. 2004, 6: R33-R38. 10.1186/ar1021.

36.

Hayashi Y, Haneji N, Hamano H, Yanagi K, Takahashi M, Ishimaru N: Effector mechanism of experimental autoimmune sialadenitis in the mouse model for primary Sjögren's syndrome. Cell Immunol. 1996, 171: 217-225.

37.

Saegusa J, Kubota H: Sialadenitis in IQI/Jic mice: a new animal model of Sjögren's syndrome. J Vet Med Sci. 1997, 59: 897-903. 10.1292/jvms.59.897.

38.

Takada K, Takiguchi M, Konno A, Inaba M: Spontaneous development of multiple glandular and extraglandular lesions in aged IQI/Jic mice: a model for primary Sjögren's syndrome. Rheumatology (Oxford). 2004, 43: 858-862. 10.1093/rheumatology/keh209.

39.

Takada K, Takiguchi M, Konno A, Inaba M: Autoimmunity against a tissue kallikrein in IQI/Jic Mice: a model for Sjögren's syndrome. J Biol Chem. 2005, 280: 3982-3988.

40.

Kaufman E, Lamster IB: The diagnostic applications of saliva - a review. Crit Rev Oral Biol Med. 2002, 13: 197-212. 10.1177/154411130201300209.

41.

Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG: Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine background. Arthritis Rheum. 2002, 46: 1390-1398. 10.1002/art.10258.

42.

Robinson CP, Yamachika S, Bounous DI, Brayer J, Jonsson R, Holmdahl R, Peck AB, Humphreys-Beher MG: A novel NOD-derived murine model of primary Sjögren's syndrome. Arthritis Rheum. 1998, 41: 150-156. 10.1002/1529-0131(199801)41:1<150::AID-ART18>3.0.CO;2-T.

43.

Lindqvist AK, Nakken B, Sundler M, Kjellen P, Jonsson R, Holmdahl R, Skarstein K: Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse. Scand J Immunol. 2005, 61: 119-127. 10.1111/j.0300-9475.2005.01550.x.

44.

Anderson MS, Bluestone JA: The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005, 23: 447-485. 10.1146/annurev.immunol.23.021704.115643.

45.

Setoguchi R, Hori S, Takahashi T, Sakaguchi S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005, 201: 723-735. 10.1084/jem.20041982.

46.

Hawke CG, Painter DM, Kirwan PD, Van Driel RR, Baxter AG: Mycobacteria, an environmental enhancer of lupus nephritis in a mouse model of systemic lupus erythematosus. Immunology. 2003, 108: 70-78. 10.1046/j.1365-2567.2003.01558.x.

47.

Quintana FJ, Pitashny M, Cohen IR: Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor. Int Immunol. 2003, 15: 11-16. 10.1093/intimm/dxg003.

48.

Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI: Blockade of lymphotoxin-β receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther. 2009, 11: R24-10.1186/ar2617.

49.

Wildenberg ME, Welzen-Coppens JM, van Helden-Meeuwsen CG, Bootsma H, Vissink A, van Rooijen N, van de Merwe JP, Drexhage HA, Versnel MA: Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome. Ann Rheum Dis. 2009, 68: 420-426. 10.1136/ard.2008.087874.

50.

Hunger RE, Carnaud C, Vogt I, Mueller C: Male gonadal environment paradoxically promotes dacryoadenitis in nonobese diabetic mice. J Clin Invest. 1998, 101: 1300-1309. 10.1172/JCI1230.

51.

Delaleu N: The Autonomy of Different Aspects of Sjögren's Syndrome and their Treatment in an Experimental Model. 2008, Bergen: University of Bergen

52.

Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K: Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis Rheum. 2006, 54: 2300-2305. 10.1002/art.21945.

53.

Nguyen CQ, Sharma A, She JX, McIndoe RA, Peck AB: Differential gene expressions in the lacrimal gland during development and onset of keratoconjunctivitis sicca in Sjögren's syndrome (SJS)-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Exp Eye Res. 2009, 88: 398-409. 10.1016/j.exer.2008.10.006.

54.

Nguyen CQ, Sharma A, Lee BH, She JX, McIndoe RA, Peck AB: Differential gene expression in the salivary gland during development and onset of xerostomia in Sjögren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse. Arthritis Res Ther. 2009, 11: R56-10.1186/ar2676.

55.

Burt RA, Watkins L, Tan IK, Wang N, Quirk F, Mackin L, Morgan P, Zhang JG, Berzins SP, Morahan G, Brodnicki TC: An NZW-derived interval on chromosome 7 moderates sialadenitis, but not insulitis in congenic nonobese diabetic mice. J Immunol. 2010, 184: 859-868. 10.4049/jimmunol.0903149.

56.

Delaleu N, Immervoll H, Cornelius J, Jonsson R: Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther. 2008, 10: R22-10.1186/ar2375.

57.

Delaleu N, Madureira AC, Immervoll H, Jonsson R: Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437-460. Arthritis Rheum. 2008, 58: 2318-2328. 10.1002/art.23656.

58.

Salam MA, Matin K, Matsumoto N, Tsuha Y, Hanada N, Senpuku H: E2f1 mutation induces early onset of diabetes and Sjögren's syndrome in nonobese diabetic mice. J Immunol. 2004, 173: 4908-4918.

59.

Matsui-Inohara H, Uematsu H, Narita T, Satoh K, Yonezawa H, Kuroda K, Ito T, Yoneda S, Kawarai T, Sugiya H, Watanabe H, Senpuku H: E2F-1-deficient NOD/SCID mice developed showing decreased saliva production. Exp Biol Med (Maywood). 2009, 234: 1525-1536. 10.3181/0905-RM-173.

60.

Kong L, Robinson CP, Peck AB, Vela-Roch N, Sakata KM, Dang H, Talal N, Humphreys-Beher MG: Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol. 1998, 16: 675-681.

61.

Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM: Primary Sjögren's syndrome and deficiency of ICA69. Lancet. 2002, 360: 1063-1069. 10.1016/S0140-6736(02)11144-5.

62.

Gordon TP, Cavill D, Neufing P, Zhang YJ, Pietropaolo M: ICA69 autoantibodies in primary Sjögren's syndrome. Lupus. 2004, 13: 483-484.

63.

DeVoss JJ, LeClair NP, Hou Y, Grewal NK, Johannes KP, Lu W, Yang T, Meagher C, Fong L, Strauss EC, Anderson MS: An autoimmune response to odorant binding protein 1a is associated with dry eye in the Aire-deficient mouse. J Immunol. 2010, 184: 4236-4246. 10.4049/jimmunol.0902434.

64.

Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, Peen E, Jonsson R, Humphreys-Beher MG: Transfer of human serum IgG to nonobese diabetic Igμ null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc Natl Acad Sci USA. 1998, 95: 7538-7543. 10.1073/pnas.95.13.7538.

65.

Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB: Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun. 2006, 26: 90-103. 10.1016/j.jaut.2005.11.004.

66.

Nguyen CQ, Gao JH, Kim H, Saban DR, Cornelius JG, Peck AB: IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse. J Immunol. 2007, 179: 382-390.

67.

Soyfoo MS, De Vriese C, Debaix H, Martin-Martinez MD, Mathieu C, Devuyst O, Steinfeld SD, Delporte C: Modified aquaporin 5 expression and distribution in submandibular glands from NOD mice displaying autoimmune exocrinopathy. Arthritis Rheum. 2007, 56: 2566-2574. 10.1002/art.22826.

68.

Ohashi Y, Tsuzaka K, Takeuchi T, Sasaki Y, Tsubota K: Altered distribution of aquaporin 5 and its C-terminal binding protein in the lacrimal glands of a mouse model for Sjögren's syndrome. Curr Eye Res. 2008, 33: 621-629. 10.1080/02713680802262819.

69.

Serreze DV, Chapman HD, Post CM, Johnson EA, Suarez-Pinzon WL, Rabinovitch A: Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol. 2001, 166: 1352-1359.

70.

Chatenoud L, Bach JF: Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse. Int Rev Immunol. 2005, 24: 247-267. 10.1080/08830180590934994.

71.

Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007, 25: 821-852. 10.1146/annurev.immunol.25.022106.141557.

72.

Yanagi K, Ishimaru N, Haneji N, Saegusa K, Saito I, Hayashi Y: Anti-120-kDa α-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome. Eur J Immunol. 1998, 28: 3336-3345. 10.1002/(SICI)1521-4141(199810)28:10<3336::AID-IMMU3336>3.0.CO;2-R.

73.

Yamano S, Atkinson JC, Baum BJ, Fox PC: Salivary gland cytokine expression in NOD and normal BALB/c mice. Clin Immunol. 1999, 92: 265-275. 10.1006/clim.1999.4759.

74.

Vosters JL, Yin H, Roescher N, Kok MR, Tak PP, Chiorini JA: Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome. Arthritis Res Ther. 2009, 11: R189-10.1186/ar2888.

75.

Hunger RE, Muller S, Laissue JA, Hess MW, Carnaud C, Garcia I, Mueller C: Inhibition of submandibular and lacrimal gland infiltration in nonobese diabetic mice by transgenic expression of soluble TNF-receptor p55. J Clin Invest. 1996, 98: 954-961. 10.1172/JCI118879.

76.

Mikulowska-Mennis A, Xu B, Berberian JM, Michie SA: Lymphocyte migration to inflamed lacrimal glands is mediated by vascular cell adhesion molecule-1/alpha(4)beta(1) integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am J Pathol. 2001, 159: 671-681. 10.1016/S0002-9440(10)61738-5.

77.

Brayer JB, Cha S, Nagashima H, Yasunari U, Lindberg A, Diggs S, Martinez J, Goa J, Humphreys-Beher MG, Peck AB: IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjögren's syndrome. Scand J Immunol. 2001, 54: 133-140. 10.1046/j.1365-3083.2001.00958.x.

78.

Cha S, Brayer J, Gao J, Brown V, Killedar S, Yasunari U, Peck AB: A dual role for interferon-gamma in the pathogenesis of Sjögren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol. 2004, 60: 552-565. 10.1111/j.0300-9475.2004.01508.x.

79.

Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB: Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum. 2008, 58: 734-743. 10.1002/art.23214.

80.

Nguyen CQ, Yin H, Lee BH, Carcamo WC, Chiorini JA, Peck AB: Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther. 2010, 12: R220-10.1186/ar3207.

81.

Nguyen CQ, Yin H, Lee BH, Chiorini JA, Peck AB: IL17: potential therapeutic target in Sjögren's syndrome using adenovirus-mediated gene transfer. Lab Invest. 2011, 91: 54-62. 10.1038/labinvest.2010.164.

82.

Hjelmervik TO, Lindqvist AK, Petersen K, Johannesson M, Stavrum AK, Johansson A, Jonsson R, Holmdahl R, Bolstad AI: The influence of the NOD Nss1/Idd5 loci on sialadenitis and gene expression in salivary glands of congenic mice. Arthritis Res Ther. 2007, 9: R99-10.1186/ar2300.

83.

Killedar SJ, Eckenrode SE, McIndoe RA, She JX, Nguyen CQ, Peck AB, Cha S: Early pathogenic events associated with Sjögren's syndrome (SjS)-like disease of the NOD mouse using microarray analysis. Lab Invest. 2006, 86: 1243-1260. 10.1038/labinvest.3700487.

84.

Nguyen CQ, Cornelius JG, Cooper L, Neff J, Tao J, Lee BH, Peck AB: Identification of possible candidate genes regulating Sjögren's syndrome-associated autoimmunity: a potential role for TNFSF4 in autoimmune exocrinopathy. Arthritis Res Ther. 2008, 10: R137-10.1186/ar2560.

85.

Rozzo SJ, Vyse TJ, Menze K, Izui S, Kotzin BL: Enhanced susceptibility to lupus contributed from the nonautoimmune C57BL/10, but not C57BL/6, genome. J Immunol. 2000, 164: 5515-5521.

86.

Hayashi Y, Utsuyama M, Kurashima C, Hirokawa K: Spontaneous development of organ-specific autoimmune lesions in aged C57BL/6 mice. Clin Exp Immunol. 1989, 78: 120-126.

87.

Bulosan M, Pauley KM, Yo K, Chan EK, Katz J, Peck AB, Cha S: Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol Cell Biol. 2009, 87: 81-90. 10.1038/icb.2008.70.

88.

Nguyen CQ, Kim H, Cornelius JG, Peck AB: Development of Sjögren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6. NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol. 2007, 179: 2318-2329.

89.

Anderson JT, Cornelius JG, Jarpe AJ, Winter WE, Peck AB: Insulin-dependent diabetes in the NOD mouse model. II. Beta cell destruction in autoimmune diabetes is a TH2 and not a TH1 mediated event. Autoimmunity. 1993, 15: 113-122. 10.3109/08916939309043886.

90.

Allison J, McClive P, Oxbrow L, Baxter A, Morahan G, Miller JF: Genetic requirements for acceleration of diabetes in non-obese diabetic mice expressing interleukin-2 in islet beta-cells. Eur J Immunol. 1994, 24: 2535-2541. 10.1002/eji.1830241041.

91.

Sharma R, Zheng L, Guo X, Fu SM, Ju ST, Jarjour WN: Novel animal models for Sjögren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice. J Autoimmun. 2006, 27: 289-296. 10.1016/j.jaut.2006.11.003.

92.

De Paiva CS, Hwang CS, Pitcher JD, Pangelinan SB, Rahimy E, Chen W, Yoon KC, Farley WJ, Niederkorn JY, Stern ME, Li DQ, Pflugfelder SC: Age-related T-cell cytokine profile parallels corneal disease severity in Sjögren's syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford). 2010, 49: 246-258. 10.1093/rheumatology/kep357.

93.

Schimpl A, Berberich I, Kneitz B, Kramer S, Santner-Nanan B, Wagner S, Wolf M, Hunig T: IL-2 and autoimmune disease. Cytokine Growth Factor Rev. 2002, 13: 369-378. 10.1016/S1359-6101(02)00022-9.

94.

Sharma R, Deshmukh US, Zheng L, Fu SM, Ju ST: X-linked Foxp3 (Scurfy) mutation dominantly inhibits submandibular gland development and inflammation respectively through adaptive and innate immune mechanisms. J Immunol. 2009, 183: 3212-3218. 10.4049/jimmunol.0804355.

95.

Saito I, Haruta K, Shimuta M, Inoue H, Sakurai H, Yamada K, Ishimaru N, Higashiyama H, Sumida T, Ishida H, Suda T, Noda T, Hayashi Y, Tsubota K: Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. J Immunol. 1999, 162: 2488-2494.

96.

Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ: Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther. 2003, 14: 1605-1618. 10.1089/104303403322542257.

97.

McGrath-Morrow S, Laube B, Tzou SC, Cho C, Cleary J, Kimura H, Rose NR, Caturegli P: IL-12 overexpression in mice as a model for Sjögren lung disease. Am J Physiol Lung Cell Mol Physiol. 2006, 291: L837-L846. 10.1152/ajplung.00134.2006.

98.

Vosters JL, Landek-Salgado MA, Yin H, Swaim WD, Kimura H, Tak PP, Caturegli P, Chiorini JA: Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum. 2009, 60: 3633-3641. 10.1002/art.24980.

99.

Tang JC, Ho FC, Chan AC, Srivastava G: Clonality of lymphomas at multiple sites in SJL mice. Lab Invest. 1998, 78: 205-212.

100.

Kimura-Shimmyo A, Kashiwamura S, Ueda H, Ikeda T, Kanno S, Akira S, Nakanishi K, Mimura O, Okamura H: Cytokine-induced injury of the lacrimal and salivary glands. J Immunother. 2002, 25 (Suppl 1): S42-S51.

101.

Shen L, Zhang C, Wang T, Brooks S, Ford RJ, Lin-Lee YC, Kasianowicz A, Kumar V, Martin L, Liang P, Cowell J, Ambrus JL: Development of autoimmunity in IL-14alpha-transgenic mice. J Immunol. 2006, 177: 5676-5686.

102.

Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, Ambrus JL: IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans. Clin Immunol. 2009, 130: 304-312. 10.1016/j.clim.2008.10.006.

103.

Gommerman JL, Browning JL: Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol. 2003, 3: 642-655. 10.1038/nri1151.

104.

Shen L, Suresh L, Wu J, Xuan J, Li H, Zhang C, Pankewycz O, Ambrus JL: A role for lymphotoxin in primary Sjögren's disease. J Immunol. 2010, 185: 6355-6363. 10.4049/jimmunol.1001520.

105.

Mackay F, Schneider P: Cracking the BAFF code. Nat Rev Immunol. 2009, 9: 491-502. 10.1038/nri2572.

106.

Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest. 2002, 109: 59-68.

107.

Fletcher CA, Sutherland AP, Groom JR, Batten ML, Ng LG, Gommerman J, Mackay F: Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol. 2006, 36: 2504-2514. 10.1002/eji.200636270.

108.

Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000, 404: 995-999. 10.1038/35010115.

109.

Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999, 190: 1697-1710. 10.1084/jem.190.11.1697.

110.

Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, Xin X, Schneider P, Tschopp J, Mackay CR, Mackay F: TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004, 172: 812-822.

111.

Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA. 1993, 90: 770-774. 10.1073/pnas.90.2.770.

112.

McCartney-Francis NL, Mizel DE, Redman RS, Frazier-Jessen M, Panek RB, Kulkarni AB, Ward JM, McCarthy JB, Wahl SM: Autoimmune Sjögren's-like lesions in salivary glands of TGF-β1-deficient mice are inhibited by adhesion-blocking peptides. J Immunol. 1996, 157: 1306-1312.

113.

Hall BE, Zheng C, Swaim WD, Cho A, Nagineni CN, Eckhaus MA, Flanders KC, Ambudkar IS, Baum BJ, Kulkarni AB: Conditional overexpression of TGF-β1 disrupts mouse salivary gland development and function. Lab Invest. 2010, 90: 543-555. 10.1038/labinvest.2010.5.

114.

Li X: Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine. 2008, 41: 105-113. 10.1016/j.cyto.2007.09.015.

115.

Qian Y, Giltiay N, Xiao J, Wang Y, Tian J, Han S, Scott M, Carter R, Jorgensen TN, Li X: Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome. Eur J Immunol. 2008, 38: 2219-2228. 10.1002/eji.200738113.

116.

Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S: Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol. 2009, 175: 1136-1147. 10.2353/ajpath.2009.081058.

117.

Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell. 1998, 93: 1159-1170. 10.1016/S0092-8674(00)81460-9.

118.

Kazerounian S, Yee KO, Lawler J: Thrombospondins in cancer. Cell Mol Life Sci. 2008, 65: 700-712. 10.1007/s00018-007-7486-z.

119.

Shim GJ, Warner M, Kim HJ, Andersson S, Liu L, Ekman J, Imamov O, Jones ME, Simpson ER, Gustafsson JA: Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjögren's syndrome. Proc Natl Acad Sci USA. 2004, 101: 12628-12633. 10.1073/pnas.0405099101.

120.

Ishimaru N, Arakaki R, Watanabe M, Kobayashi M, Miyazaki K, Hayashi Y: Development of autoimmune exocrinopathy resembling Sjögren's syndrome in estrogen-deficient mice of healthy background. Am J Pathol. 2003, 163: 1481-1490. 10.1016/S0002-9440(10)63505-5.

121.

Ishimaru N, Arakaki R, Omotehara F, Yamada K, Mishima K, Saito I, Hayashi Y: Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands. Mol Cell Biol. 2006, 26: 2924-2935. 10.1128/MCB.26.8.2924-2935.2006.

122.

Ishimaru N, Arakaki R, Yoshida S, Yamada A, Noji S, Hayashi Y: Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med. 2008, 205: 2915-2927. 10.1084/jem.20080174.

123.

Yokota Y: Id and development. Oncogene. 2001, 20: 8290-8298. 10.1038/sj.onc.1205090.

124.

Quong MW, Romanow WJ, Murre C: E protein function in lymphocyte development. Annu Rev Immunol. 2002, 20: 301-322. 10.1146/annurev.immunol.20.092501.162048.

125.

Li H, Dai M, Zhuang Y: A T cell intrinsic role of Id3 in a mouse model for primary Sjögren's syndrome. Immunity. 2004, 21: 551-560. 10.1016/j.immuni.2004.08.013.

126.

Guo Z, Li H, Han M, Xu T, Wu X, Zhuang Y: Modeling Sjögren's syndrome with Id3 conditional knockout mice. Immunol Lett. 2011, 135: 34-42. 10.1016/j.imlet.2010.09.009.

127.

Hayakawa I, Tedder TF, Zhuang Y: B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. Immunology. 2007, 122: 73-79. 10.1111/j.1365-2567.2007.02614.x.

128.

Sellam J, Miceli-Richard C, Gottenberg JE, Proust A, Ittah M, Lavie F, Loiseau P, Mariette X: Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?. Rheumatology (Oxford). 2008, 47: 437-441.

129.

Fruman DA, Bismuth G: Fine tuning the immune response with PI3K. Immunol Rev. 2009, 228: 253-272. 10.1111/j.1600-065X.2008.00750.x.

130.

Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, Fruman DA: Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci USA. 2006, 103: 16882-16887. 10.1073/pnas.0607984103.

131.

Vallabhapurapu S, Karin M: Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol. 2009, 27: 693-733. 10.1146/annurev.immunol.021908.132641.

132.

Ou TT, Lin CH, Lin YC, Li RN, Tsai WC, Liu HW, Yen JH: IκBα promoter polymorphisms in patients with primary Sjögren's syndrome. J Clin Immunol. 2008, 28: 440-444. 10.1007/s10875-008-9212-5.

133.

Peng B, Ling J, Lee AJ, Wang Z, Chang Z, Jin W, Kang Y, Zhang R, Shim D, Wang H, Fleming JB, Zheng H, Sun SC, Chiao PJ: Defective feedback regulation of NF-κB underlies Sjögren's syndrome in mice with mutated kappaB enhancers of the IκBα promoter. Proc Natl Acad Sci USA. 2010, 107: 15193-15198. 10.1073/pnas.1005533107.

134.

Mix E, Meyer-Rienecker H, Zettl UK: Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol. 2008, 255 (Suppl 6): 7-14.

135.

Hegen M, Keith JC, Collins M, Nickerson-Nutter CL: Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 1505-1515.

136.

Scofield RH, Asfa S, Obeso D, Jonsson R, Kurien BT: Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjögren's syndrome. J Immunol. 2005, 175: 8409-8414.

137.

Kurien BT, Asfa S, Li C, Dorri Y, Jonsson R, Scofield RH: Induction of oral tolerance in experimental Sjögren's syndrome autoimmunity. Scand J Immunol. 2005, 61: 418-425. 10.1111/j.1365-3083.2005.01593.x.

138.

Ohlsson M, Jonsson R, Brokstad KA: Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol. 2002, 56: 456-469. 10.1046/j.1365-3083.2002.01072_79.x.

139.

Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, Sjostrand M, Eloranta ML, Ni Gabhann J, Winqvist O, Sundelin B, Jefferies CA, Rozell B, Kuchroo VK, Wahren-Herlenius M: Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009, 206: 1661-1671. 10.1084/jem.20090585.

140.

Iizuka M, Wakamatsu E, Tsuboi H, Nakamura Y, Hayashi T, Matsui M, Goto D, Ito S, Matsumoto I, Sumida T: Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjögren's syndrome-like sialoadenitis. J Autoimmun. 2010, 35: 383-389. 10.1016/j.jaut.2010.08.004.

141.

Inagaki Y, Jinno-Yoshida Y, Hamasaki Y, Ueki H: A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren's syndrome. J Dermatol Sci. 1991, 2: 147-154. 10.1016/0923-1811(91)90060-B.

142.

Nishimori I, Bratanova T, Toshkov I, Caffrey T, Mogaki M, Shibata Y, Hollingsworth MA: Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. J Immunol. 1995, 154: 4865-4873.

143.

Fleck M, Kern ER, Zhou T, Lang B, Mountz JD: Murine cytomegalovirus induces a Sjögren's syndrome-like disease in C57Bl/6-lpr/lpr mice. Arthritis Rheum. 1998, 41: 2175-2184. 10.1002/1529-0131(199812)41:12<2175::AID-ART12>3.0.CO;2-I.

144.

Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U, Mountz JD: Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum. 2001, 44: 964-973. 10.1002/1529-0131(200104)44:4<964::AID-ANR154>3.0.CO;2-5.

Titel: Sjögren's syndrome: studying the disease in mice
verfasst von: Nicolas Delaleu
Cuong Q Nguyen
Ammon B Peck
Roland Jonsson
Publikationsdatum: 01.12.2011
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 3/2011
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3313

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Sjögren's syndrome: studying the disease in mice

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Videoradiographic analysis of the range of motion in unilateral experimental knee joint arthritis in rats

Defective response of CD4+ T cells to retinoic acid and TGFβ in systemic lupus erythematosus

The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin